BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 20559114)

  • 1. Different patterns of expression of the erbB family of receptor tyrosine kinases in common nevi, dysplastic nevi, and primary malignant melanomas: an immunohistochemical study.
    Feinmesser M; Veltman V; Morgenstern S; Tobar A; Gutman H; Kaganovsky E; Tzabari C; Sulkes J; Okon E
    Am J Dermatopathol; 2010 Oct; 32(7):665-75. PubMed ID: 20559114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi.
    Sand M; Gambichler T; Sand D; Altmeyer P; Stuecker M; Bechara FG
    Eur J Dermatol; 2011; 21(1):18-21. PubMed ID: 21262599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
    Fullen DR; Zhu W; Thomas D; Su LD
    J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
    Singh RS; Diwan AH; Zhang PS; Prieto VG
    J Cutan Pathol; 2007 Mar; 34(3):220-5. PubMed ID: 17302605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mast cells in melanocytic skin lesions. An immunohistochemical and quantitative study.
    Dyduch G; Okoń K; Pescarini E
    Pol J Pathol; 2011 Sep; 62(3):139-44. PubMed ID: 22102069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
    Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
    Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
    Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
    Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
    Boyd AS; Shakhtour B; Shyr Y
    J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
    Montone KT; van Belle P; Elenitsas R; Elder DE
    Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis of melanoma precursor lesions.
    Wang Y; Rao U; Mascari R; Richards TJ; Panson AJ; Edington HD; Shipe-Spotloe JM; Donnelly SS; Kirkwood JM; Becker D
    Cell Growth Differ; 1996 Dec; 7(12):1733-40. PubMed ID: 8959342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fascin expression in melanocytic lesions of the skin.
    YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
    Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin D1 expression in melanocytic lesions of the skin.
    Ramirez JA; Guitart J; Rao MS; Diaz LK
    Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
    Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
    J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Widespread expression of ErbB2, ErbB3 and ErbB4 in non-human primate brain.
    Thompson M; Lauderdale S; Webster MJ; Chong VZ; McClintock B; Saunders R; Weickert CS
    Brain Res; 2007 Mar; 1139():95-109. PubMed ID: 17280647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma.
    Giehl KA; Nägele U; Volkenandt M; Berking C
    J Cutan Pathol; 2007 Jan; 34(1):7-14. PubMed ID: 17214848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleolin protein expression in cutaneous melanocytic lesions.
    Mourmouras V; Cevenini G; Cosci E; Epistolato MC; Biagioli M; Barbagli L; Luzi P; Mannucci S; Miracco C
    J Cutan Pathol; 2009 Jun; 36(6):637-46. PubMed ID: 19515042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
    Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
    J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder.
    Chow NH; Chan SH; Tzai TS; Ho CL; Liu HS
    Clin Cancer Res; 2001 Jul; 7(7):1957-62. PubMed ID: 11448910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.